Print Friendly, PDF & Email

10 ways cell therapy and biopharma have changed in 2017 and why it matters

From microscopic processes to large-scale manufacturing of biologics, life sciences has made massive progress that sets the stage for rapidly changing healthcare


1. 3D Printing Meets Biopharma: How Two Engineers Turned a Vision and One Printer into a Center that May Improve Healthcare

Two GE Healthcare’s engineers, inspired by the idea of Additive Manufacturing, also known as industrial 3D printing, envisioned a space where engineers and manufacturers could collaborate under the same roof to develop and produce parts for healthcare equipment, especially for the booming biopharma industry.  This space has now become GE Healthcare’s first Innovative Design and Advanced Manufacturing Technology Center in Europe. [Read more…]

2. T-CELL: The Universe’s Tiniest Superhero May Be Most Powerful Of All

While cancer has typically been treated with a combination of chemotherapy, radiation and clinical medications, cell therapy adds a radically new approach to the mix.  Immune cells are removed from the patient – the T-cells – and reprogrammed to identify and destroy cancer cells. The reprogrammed T-cells are then put back into the patient, to find the bad guys and attack. Visit this cell therapy lab to understand how that works. [Read more…]


3. “Like turbocharging your car”: The future of personalized medicine could hinge on a microscopic process from Sweden

Every day, patients around the world rely on monoclonal antibody therapies to treat the most devastating illnesses, including cancer, Alzheimer’s and autoimmune diseases. The scaling of these potentially life-saving treatments is not easy though. But making the biopharmaceuticals that treat the most devastating illnesses just got faster and easier. MabSelect PrismA is a new Protein A chromatography resin that will help biopharmaceutical manufacturers improve their monoclonal antibody purification capacity by up to 40%. [Read more…]

4. One reason clinical trials for Alzheimer’s disease have failed — And the digital biomarker that could help address that

Introducing a new disease-modifying therapy, from research through to launch, is an extremely complex process, with lengthy and expensive drug development cycles. While clinical trial design has improved, the failure rate is still significant, especially in areas such as neurology. A new a new predictive analytics tool could positively increase the rate at which effective disease-modifying therapies become available. [Read more…]


5. The Law of Thaw: How a New Technology Improves the Delivery of Cell Therapies

Until now, thawing cellular therapies was an imprecise practice. The treatments are carefully developed by harvesting cells, sometimes from the patient’s own blood, and sending them to a lab, where they’re manipulated and cultured into millions of cells. Then they’re frozen below -200˚ F and shipped to the patient’s treatment location, where they’re thawed out and injected back into the bloodstream to attack unwanted, cancerous cells. A new thawing technology helps to get “living medicines” to patients around the world and providing physicians with reliable data. [Read more…]


6. Booming Biologics Industry Calls for Additional Production Capacity

Biopharmaceuticals are the world’s fastest-growing class of medicines. Their development and manufacturing processes are demanding and complicated. Many biopharmaceutical companies choose to outsource their biologics development and manufacturing to contract development and manufacturing organizations (CDMOs), which take the burden of manufacturing for biopharma companies. It’s why, one of the world’s largest CDMOs, Fujifilm Diosynth Biotechnologies, decided to use its role in the booming biologics industry to address this challenge, by opening and building the UK’s first single-use facility in record time to increase their production capacita of biopharmaceuticals. Find out more here. [Read more…]


7. The Doctor’s Carousel: Diagnosing Parkinson’s Disease

Parkinson’s disease (PD) is a neurodegenerative disease that today affects an estimated one million people in the United States and more than five million people worldwide. This is the story of how one man went from 100 doctors visits in 10 months to a diagnosis that changed his life. [Read more…]


8. Biopharma is making its own luck in Ireland

In September 2016, GE announced a training collaboration with the National Institute for Bioprocessing Research and Training (NIBRT) to build expertise in next-generation, single-use manufacturing technology for biotech and biopharma companies. The NIBRT-GE Single-use Training Center of Excellence at NIBRT’s facility in Dublin, Ireland, will train approximately 1,500 people per year in the application and use of single-use technologies. [Read more…]


9. Race to Market: Collaborating to Accelerate Cell Therapy

The Centre for Advanced Therapeutic Cell Technologies (CATCT) in Toronto is a collaboration between GE Healthcare, the Government of Canada, and CCRM – a leader in developing and commercializing regenerative medicine technologies, and cell and gene therapies. Launched in January 2016 and officially opened in September 2017 in Toronto, It’s designed to help small to large biotech companies and research institutions scale faster and develop new processes to enable them to ultimately offer cell therapy to thousands of patients. [Read more…]

10. Leading Light: One Microscope, Lots Of Nobel Prize Winners

75 percent of recent winners of the Nobel Prize relied on a version of the DeltaVision microscope from GE Healthcare during their research. This year’s winners, for example, used it to peek inside our biological clock and elucidate its inner workings. This type of “peeking” wasn’t possible up until 25 years ago. Find out more about scientists’ work with DeltaVision. [Read more…]